One of the two most common drugs used to treat age-related macular degeneration (AMD) appears better than the other, a new, small study suggests. Among 106 patients with “wet” age-related macular degeneration, 50% of those treated with aflibercept (Eylea) could be weaned off the drug after one year, compared with only 17% of those treated… read on > read on >







